Clinical trials: Drug Specific Antibodies
Advanced Solid Tumors
First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts.
- Trial name
- NCT07700160
- Testing
- VBC108
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 230 people
- Sponsor
- VelaVigo Bio Inc
Kidney Disease, End-Stage, Donor Specific Antibodies
Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant
In spite of conventional immunosuppression with lymphocyte-depleting induction followed by tacrolimus- and mycophenolate-based regimens, African American (AA) renal transplant recipients experience higher rates of acute rejection…
- Conditions
- Kidney Disease, End-Stage, Donor Specific Antibodies, Acute Rejection of Renal Transplant
- Trial name
- NCT04665310
- Testing
- Envarsus XR
- Volunteers
- 46 people
- Sponsor
- The Methodist Hospital Research Institute
Advanced Solid Tumor, Homologous Recombination Deficiency
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
- Conditions
- Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency
- Trial name
- NCT06525298
- Testing
- EIS-12656, Olaparib, Trastuzumab deruxtecan
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Eisbach Bio GmbH
Thrombocytopenia, Antibodies Drug Specific
Immunogenicity and Thrombotic Potential of Circulating Protamine-heparin Complexes in Cardiac Surgery Patients
The primary aim of this study was to describe the prevalence and time course of the occurrence of protamine/heparin antibodies in patients undergoing cardiac surgery on cardiopulmonary bypass.
- Trial name
- NCT06565364
- Testing
- "ZYMUTEST™ HIA" immunoglobulin g ELISA (enzyme-linked immunosorbent assay )
- Where
- Austria
- Volunteers
- 160 people
- Sponsor
- Medical University of Vienna
Metastatic Prostate Cancer
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate cancer (mPC).
- Trial name
- ARX517 (NCT04662580)
- Testing
- ARX517, Apalutamide, Abiraterone acetate
- Where
- 12 sites in United States
- Volunteers
- 183 people
- Sponsor
- Janssen Research & Development, LLC
Participants With Advanced Solid Tumor Malignancies
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed by BOIN design to identify the MTD and/or RP2D with potential backfill…
- Trial name
- NCT07136779
- Testing
- VBC101
- Where
- 5 sites in United States
- Volunteers
- 310 people
- Sponsor
- VelaVigo Bio Inc
Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection
Background: People with HIV usually take a combination of 2 or more anti-HIV drugs daily to help manage their infection. Sometimes, however, HIV becomes resistant to these drugs, and the infection cannot be treated.
- Trial name
- NCT05582694
- Testing
- UB-421
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Antibody-mediated Rejection, Kidney Transplant; Complications
Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
Antibody mediated rejection (ABMR) is a unique, significant and often severe form of allograft rejection. This single center, phase I/II, open label single-arm exploratory study focuses on enrolling ten patients with biopsy…
- Conditions
- Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form
- Trial name
- NCT03380377
- Testing
- Clazakizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanley Jordan, MD
Advanced Solid Tumors
VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors
Detailed Description: This is a multicenter, open-label, multiple-dose, first in human(FIH) Phase 1/2a trial. The Phase 1 portion uses the Bayesian optimal interval (BOIN) design to escalate doses and determine the maximum…
- Trial name
- NCT07772934
- Testing
- VBC117
- Where
- 12 sites in Australia, China
- Volunteers
- 260 people
- Sponsor
- VelaVigo Bio Inc
Cholangitis, Secondary Biliary, Treatment Compliance
Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy
Application of multi-center, prospective study on the severity of postoperative cholangitis biliary atresia classification, according to the degree of cholangitis targeted therapy, to improve the therapeutic effect of…
- Conditions
- Cholangitis, Secondary Biliary, Treatment Compliance, Antibodies Drug Specific
- Trial name
- NCT04370145
- Testing
- Sulperazon, Teicoplanin, Meropenem Injection
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Tongji Hospital
Prostate Cancer
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301EXT is an open-label, nonrandomized, phase 1 extension study of PSMA ADC administered IV in subjects with progressive CMPC that has progressed after prior…
- Trial name
- NCT01414296
- Testing
- PSMA ADC
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Renal Allograft Recipients
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
The purpose of this study is to evaluate the benefits and risks of conversion of existing adolescent kidney allograft recipients aged 12 to less than 18 years of age to a belatacept-based immunosuppressive regimen as compared to…
- Trial name
- NCT04877288
- Testing
- Belatacept, Tacrolimus, Cyclosporine A
- Where
- 38 sites in United States, Argentina and 8 more
- Volunteers
- 102 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination
The purpose of this study is to see if giving a vaccine (Remune) is effective in HIV-positive patients who are also taking anti-HIV therapy.
- Trial name
- NCT00006153
- Testing
- HIV-1 Immunogen
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02552121
- Testing
- Tisotumab vedotin (HuMax-TF-ADC)
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Drug-specific Antibodies
A Multi-center Clinical Study of Drug Antibody and Precision Transfusion in China
Blood samples for hemolytic anemia in patients treated with one or more of the antibiotics including piperacillin, amoxicillin, cefazolin, cefuroxime, ceftriaxone, cefoxitin sodium, and vancomycin were screened for the production…
- Trial name
- NCT05606302
- Where
- China
- Volunteers
- 14,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hypoglycemia, Diabetes Mellitus
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
Up to two hundred (200) adult participants with type 1 diabetes (T1D) aged 18 to 75 years will be selected for inclusion in the study.
- Conditions
- Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
- Trial name
- NCT02171130
- Testing
- Nasal Glucagon
- Where
- 9 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- Eli Lilly and Company
Metastatic Castration-Resistant Prostatic Cancer
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with…
- Trial name
- NCT07258407
- Testing
- TD001
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 180 people
- Sponsor
- T.O.A.D. Oncology SA
Covid19, Respiratory Viral Infection
The Evaluation of Cellular and Humoral Immunity to COVID-19 in Moscow Residents
The aim of the research is to estimate the levels of cellular and humoral immunity to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among Moscow residents over 18 years old.
- Trial name
- NCT04898140
- Testing
- SARS-CoV-2 specific IgM and IgG detection, ELISpot: detection of the T cells specific to different SARS-CoV-2 proteins, Flow cytometry: detection of the SARS-CoV-2 specific T-helpers and cytotoxic T lymphocytes
- Where
- Russia
- Volunteers
- 5,340 people, healthy volunteers welcome
- Sponsor
- Moscow Department of Health
Prostate Cancer
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistant, metastatic prostate cancer…
- Trial name
- NCT01414283
- Testing
- PSMA ADC
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Hemophilia A, Hemophilia B
German Pediatric Hemophilia Research Database
The German Pediatric Hemophilia Research Database will collect data on the prophylactic and therapeutic use of factor concentrates, complications, outcome measures (joint scores, QoL) and living circumstances in newly diagnosed…
- Conditions
- Hemophilia A, Hemophilia B, Children, Drug Specific Antibodies
- Trial name
- GEPHARD (NCT02912143)
- Testing
- documentation only
- Where
- Germany
- Volunteers
- 800 people
- Sponsor
- Goethe University